TRIO-TECH INTERNATIONAL (TRT) Stock Fundamental Analysis

USA • NYSE Arca • NYSEARCA:TRT • US8967122057

5.22 USD
-0.14 (-2.61%)
At close: Feb 6, 2026
5.4649 USD
+0.24 (+4.69%)
After Hours: 2/6/2026, 8:09:09 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

TRT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 113 industry peers in the Semiconductors & Semiconductor Equipment industry. The financial health of TRT is average, but there are quite some concerns on its profitability. TRT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • TRT had negative earnings in the past year.
  • In the past year TRT had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: TRT reported negative net income in multiple years.
  • In the past 5 years TRT always reported a positive cash flow from operatings.
TRT Yearly Net Income VS EBIT VS OCF VS FCFTRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M 4M 6M 8M

1.2 Ratios

  • The Return On Assets of TRT (-0.10%) is comparable to the rest of the industry.
  • With a Return On Equity value of -0.12%, TRT perfoms like the industry average, outperforming 48.67% of the companies in the same industry.
  • With a Return On Invested Capital value of 0.34%, TRT perfoms like the industry average, outperforming 47.79% of the companies in the same industry.
  • TRT had an Average Return On Invested Capital over the past 3 years of 2.81%. This is significantly below the industry average of 10.72%.
Industry RankSector Rank
ROA -0.1%
ROE -0.12%
ROIC 0.34%
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
TRT Yearly ROA, ROE, ROICTRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • TRT has a Operating Margin (0.42%) which is in line with its industry peers.
  • TRT's Operating Margin has declined in the last couple of years.
  • TRT has a worse Gross Margin (25.07%) than 75.22% of its industry peers.
  • TRT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.42%
PM (TTM) N/A
GM 25.07%
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
TRT Yearly Profit, Operating, Gross MarginsTRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TRT is destroying value.
  • TRT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, TRT has more shares outstanding
  • The debt/assets ratio for TRT has been reduced compared to a year ago.
TRT Yearly Shares OutstandingTRT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
TRT Yearly Total Debt VS Total AssetsTRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • An Altman-Z score of 4.04 indicates that TRT is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of TRT (4.04) is comparable to the rest of the industry.
  • TRT has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • TRT has a Debt to Equity ratio of 0.02. This is in the better half of the industry: TRT outperforms 69.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 4.04
ROIC/WACC0.03
WACC10.83%
TRT Yearly LT Debt VS Equity VS FCFTRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 5.03 indicates that TRT has no problem at all paying its short term obligations.
  • The Current ratio of TRT (5.03) is better than 73.45% of its industry peers.
  • TRT has a Quick Ratio of 4.67. This indicates that TRT is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TRT (4.67) is better than 76.99% of its industry peers.
Industry RankSector Rank
Current Ratio 5.03
Quick Ratio 4.67
TRT Yearly Current Assets VS Current LiabilitesTRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • TRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -105.27%.
  • Looking at the last year, TRT shows a very negative growth in Revenue. The Revenue has decreased by -13.81% in the last year.
  • Measured over the past years, TRT shows a small growth in Revenue. The Revenue has been growing by 1.14% on average per year.
EPS 1Y (TTM)-105.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.71%
Revenue 1Y (TTM)-13.81%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%9.49%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRT Yearly Revenue VS EstimatesTRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • TRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRT Price Earnings VS Forward Price EarningsTRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • 100.00% of the companies in the same industry are more expensive than TRT, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.53
TRT Per share dataTRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for TRT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRIO-TECH INTERNATIONAL

NYSEARCA:TRT (2/6/2026, 8:09:09 PM)

After market: 5.4649 +0.24 (+4.69%)

5.22

-0.14 (-2.61%)

Chartmill FA Rating
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)11-10
Earnings (Next)02-11
Inst Owners23.91%
Inst Owner Change0.12%
Ins Owners25.8%
Ins Owner Change0.73%
Market Cap22.71M
Revenue(TTM)36.47M
Net Income(TTM)-41.00K
Analysts0
Price TargetN/A
Short Float %N/A
Short Ratio1.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.62
P/FCF N/A
P/OCF 61.2
P/B 0.67
P/tB 0.67
EV/EBITDA 0.53
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)0.09
OCFY1.63%
SpS8.38
BVpS7.82
TBVpS7.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.1%
ROE -0.12%
ROCE 0.44%
ROIC 0.34%
ROICexc 0.66%
ROICexgc 0.66%
OM 0.42%
PM (TTM) N/A
GM 25.07%
FCFM N/A
ROA(3y)2.01%
ROA(5y)2%
ROE(3y)2.82%
ROE(5y)2.96%
ROIC(3y)2.81%
ROIC(5y)N/A
ROICexc(3y)5.18%
ROICexc(5y)N/A
ROICexgc(3y)5.18%
ROICexgc(5y)N/A
ROCE(3y)3.55%
ROCE(5y)N/A
ROICexgc growth 3Y-59.08%
ROICexgc growth 5YN/A
ROICexc growth 3Y-59.08%
ROICexc growth 5YN/A
OM growth 3Y-57.25%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y3.52%
F-Score4
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.2
Cap/Depr 35.28%
Cap/Sales 2.65%
Interest Coverage 3.3
Cash Conversion 12.82%
Profit Quality N/A
Current Ratio 5.03
Quick Ratio 4.67
Altman-Z 4.04
F-Score4
WACC10.83%
ROIC/WACC0.03
Cap/Depr(3y)45.5%
Cap/Depr(5y)44.1%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-105.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.71%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.81%
Revenue growth 3Y-6.11%
Revenue growth 5Y1.14%
Sales Q2Q%9.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.65%
EBIT growth 3Y-59.86%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-127.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.35%
OCF growth 3Y-44.07%
OCF growth 5Y-34.21%

TRIO-TECH INTERNATIONAL / TRT FAQ

Can you provide the ChartMill fundamental rating for TRIO-TECH INTERNATIONAL?

ChartMill assigns a fundamental rating of 3 / 10 to TRT.


Can you provide the valuation status for TRIO-TECH INTERNATIONAL?

ChartMill assigns a valuation rating of 1 / 10 to TRIO-TECH INTERNATIONAL (TRT). This can be considered as Overvalued.


Can you provide the profitability details for TRIO-TECH INTERNATIONAL?

TRIO-TECH INTERNATIONAL (TRT) has a profitability rating of 3 / 10.


What is the financial health of TRIO-TECH INTERNATIONAL (TRT) stock?

The financial health rating of TRIO-TECH INTERNATIONAL (TRT) is 5 / 10.